Navigation Links
Sangart, Inc. Receives $1.1 Million Grant Award from the United States Department of Defense for Further Development of MP4 Molecule in Trauma
Date:10/6/2010

SAN DIEGO, Oct. 6 /PRNewswire/ -- Sangart, Inc., today announced that it has been awarded a $1.1 million grant from the U.S. Department of Defense to support the development of its novel product platform based on the MP4 molecule, an investigational biopharmaceutical product designed to enhance the perfusion and oxygenation of oxygen-deprived tissues and provide targeted oxygen delivery to the capillaries in severely injured trauma patients. This award funds further pre-clinical development of the MP4 molecule in traumatic hemorrhage and ischemia in support of its current and future clinical programs.  

The award is being issued as part of the Defense Medical Research and Development Program, which provides grants in support of research designed to advance state-of-the-art solutions for world-class medical care for United States warfighters.

"We are honored to receive this grant from the Department of Defense," said Brian O'Callaghan, President and Chief Executive Officer of Sangart. "This grant supports our efforts in continuing the development of medicines designed to enhance the delivery of oxygen to tissues and organs that are oxygen deprived and supports our continued commitment to bringing new treatment options for warfighters and civilian patients suffering an acute traumatic injury."

Physical trauma is a serious injury with profound and lasting consequences. Traumatic injuries, including both penetrating trauma injuries such as bullet and knife wounds and blunt trauma from car accidents and falls, cause the death of over 5 million people each year world-wide. According to the Centers for Disease Control and Prevention (CDC), unintentional injury kills more people between the ages of one and 44 than any other disease or illness. Uncontrolled post-traumatic bleeding and resultant shock is the leading cause of potentially preventable death among military and civilian trauma patients.

About MP4Sangart's product platform is based on the MP4 molecule, an investigational biopharmaceutical product designed to enhance the perfusion of oxygen-deprived (ischemic) tissues and provide targeted oxygen delivery in the capillaries. Using a novel pegylation approach, Sangart produces the MP4 molecule designed at the optimal oxygen affinity, diffusion potential and molecular size to perfuse capillaries and target oxygen delivery to tissues specifically at risk of ischemia.

About SangartSangart is a global biopharmaceutical company dedicated to developing life-saving medicines specifically designed to enhance the perfusion and oxygenation of ischemic (oxygen deprived) tissues through targeted oxygen delivery. Based on more than a decade of research, Sangart has refined the pegylation of human hemoglobin to create a molecule, MP4, with the ability to carry oxygen through the circulatory system to prevent and treat ischemia.

To learn more about Sangart, please visit the company's website at www.sangart.com.Media Contact:Marites Cristobal CoulterEdelman Public Relations

Office: 323-202-1424Marites.Cristobal@edelman.com

Cell: 415-819-2214
'/>"/>

SOURCE Sangart, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangart, Inc. Reports Positive Phase IIa Data for Novel Oxygen Therapeutic Agent MP4OX in Severe Trauma Patients
2. Sangart, Inc. Receives European Orphan Drug Designation for the Use of MP4CO in Patients With Sickle Cell Disease
3. Sangart, Inc. Completes Series F Funding Round
4. Sangart, Inc. Announces Key Executive Appointments and Company Restructuring
5. EarlySenses EverOn(R) Central Display Station (CDS) Receives FDA Clearance
6. Maven Biotechnologies Receives $1.96 Million From the National Institutes of Health (NIH) to Develop Their LFIRE™ Label-Free Detection Technology for Proteomics
7. Collagen Matrix, Inc. Receives FDA 510(k) Clearance for New Collagen Dental Membrane Based on Porcine Collagen Platform Technology
8. Xiaoguang Meng receives honorary master of engineering from Stevens
9. AMT Receives Orphan Drug Designation From the U.S. Food and Drug Administration Duchenne Muscular Dystrophy Gene Therapy
10. Professor Leroux From ETH Receives the Debiopharm Life Sciences Award 2010
11. NephRx Corp. Receives Orphan Drug Designation for NX001 for Prevention of Delayed Kidney Graft Function
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2017)... ... 10, 2017 , ... For the second time in three ... Mentoring Award. Representatives of the FirstHand program travelled to Washington, D.C. Tuesday, October ... US2020’s mission is to change the trajectory of STEM education in America by ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/10/2017)... BARBARA, CALIFORNIA (PRWEB) , ... October 10, 2017 ... ... management, technological innovation and business process optimization firm for the life sciences and ... BoxWorks conference in San Francisco. , The presentation, “Automating GxP Validation ...
(Date:10/9/2017)... 9, 2017  BioTech Holdings announced today identification ... its ProCell stem cell therapy prevents limb loss ... Company, demonstrated that treatment with ProCell resulted in ... as compared to standard bone marrow stem cell ... in reduction of therapeutic effect.  ...
Breaking Biology Technology:
(Date:5/23/2017)... GENOA, Italy , May 23, 2017  Hunova, the first robotic ... and trunk, has been officially launched in Genoa, Italy ... Europe and the USA . The ... launched on the market by the IIT spin-off Movendo Technology thanks to ... view the Multimedia News Release, please click: ...
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
(Date:4/11/2017)... , April 11, 2017 Crossmatch®, ... secure authentication solutions, today announced that it has ... Advanced Research Projects Activity (IARPA) to develop next-generation ... program. "Innovation has been a driving ... Thor program will allow us to innovate and ...
Breaking Biology News(10 mins):